Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingFORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (
NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care PortfolioLaunch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgeryGlobal ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataInteloCommercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling StudiesNanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activitySignificant dose-dependent suppression of pulmonary viral replication in vivoStrong oral bioavailability and preferential lung enrichment across multiple species
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular ConditionsFORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (
NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityA New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
